Report error Found 372 of ic50 data for polymerid = 4690,50004545
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 12nMAssay Description:In vitro JOSD1 activity assay was carried out with Ubiquitin-AMC assay. The Ubiquitin-AMC assay was carried out as previously described (Wernig, et a...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 73nMAssay Description:In vitro JOSD1 activity assay was carried out with Ubiquitin-AMC assay. The Ubiquitin-AMC assay was carried out as previously described (Wernig, et a...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 89nMAssay Description:In vitro JOSD1 activity assay was carried out with Ubiquitin-AMC assay. The Ubiquitin-AMC assay was carried out as previously described (Wernig, et a...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 90nMAssay Description:In vitro JOSD1 activity assay was carried out with Ubiquitin-AMC assay. The Ubiquitin-AMC assay was carried out as previously described (Wernig, et a...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 100nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 100nMAssay Description:In vitro JOSD1 activity assay was carried out with Ubiquitin-AMC assay. The Ubiquitin-AMC assay was carried out as previously described (Wernig, et a...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 100nMAssay Description:In vitro JOSD1 activity assay was carried out with Ubiquitin-AMC assay. The Ubiquitin-AMC assay was carried out as previously described (Wernig, et a...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 104nMAssay Description:In vitro JOSD1 activity assay was carried out with Ubiquitin-AMC assay. The Ubiquitin-AMC assay was carried out as previously described (Wernig, et a...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 155nMAssay Description:In vitro JOSD1 activity assay was carried out with Ubiquitin-AMC assay. The Ubiquitin-AMC assay was carried out as previously described (Wernig, et a...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 230nMAssay Description:Inhibition of UCHL1 (unknown origin) using Ub-AMC as substrate preincubated with enzyme for 1 hr followed by substrate addition and measured for 1 hr...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 230nMAssay Description:Inhibition of UCHL1 (unknown origin) using Ub-Rho-Morpholine as substrate preincubated with enzyme for 1 hr followed by substrate addition and measur...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 230nMAssay Description:Inhibition of UCHL1 (unknown origin) using Ub-Rho-morpholine as substrate preincubated for 30 mins followed by substrate addition by fluorescence bas...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 420nMAssay Description:In vitro JOSD1 activity assay was carried out with Ubiquitin-AMC assay. The Ubiquitin-AMC assay was carried out as previously described (Wernig, et a...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase isozyme L1(Human)
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
DANA-FARBER CANCER INSTITUTE, INC.
US Patent
Affinity DataIC50: 550nMAssay Description:Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p...More data for this Ligand-Target Pair
